CHICAGO — AU-011 helped preserve vision in patients with early-stage choroidal melanoma, according to a study presented at the American Academy of Ophthalmology meeting.
Ivana K. Kim, MD, MBA, and colleagues enrolled 20 patients in an ongoing phase 2 trial of AU-011 (belzupacap sarotalocan, Aura Biosciences), delivered via suprachoroidal administration, according to a company press release. The trial is assessing the safety and preliminary efficacy of single and multiple ascending doses of belzupacap sarotalocan for up to three cycles of treatment. It included three single-dose cohorts